Clinical Data’s Cogenics Division to Provide Global Genotyping Solutions for Lundbeck’s Clinical Studies
News Jul 16, 2008
Clinical Data, Inc. has announced that its Cogenics® division has entered into a Scientific Research & Development Agreement with H. Lundbeck A/S to support its ongoing clinical studies with genotyping solutions on a global basis.
Lundbeck is an international pharmaceutical company engaged in the research and development, production, marketing and sale of drugs for the treatment of psychiatric and neurological disorders.
Under the agreement, Cogenics will employ its clinical genotyping platforms and expertise based in Morrisville, North Carolina and Bernried, Germany, to support Lundbeck’s clinical studies world-wide, initially focusing on Lundbeck’s Phase I studies. The term of the agreement is open-ended and the parties intend to collaborate on multiple projects going forward.
“This agreement with Lundbeck underscores Cogenics’ leading position in the clinical genotyping field, and we are very pleased to form this partnership,” says Michael Lutz, Global General Manager of Cogenics.
“Having conducted more than 1700 genotyping studies to support clinical drug development, we are well positioned to provide value-added genotyping solutions to Lundbeck on a global basis and in a consistent, high quality manner.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019